Posted by Michael Wonder on 13 May 2021
Daiichi Sankyo submits application for additional indication of mirogabalin in Japan
13 May 2021 - Daiichi Sankyo today announced that it has submitted a supplemental new drug application for mirogabalin besylate for an additional indication related to central neuropathic pain in Japan.
This application is based on the results from a Phase 3 trial conducted in patients with central neuropathic pain.
